Monitor upcoming data readouts for NMRA-511 (AD agitation, Q4 2026) and NMRA-898 (schizophrenia, H2 2026) as key catalysts. Cash runway into Q3 2027 provides no near-term financing urgency, but any clinical setbacks could pressure the stock given the poor historical performance.
Price Chart
Executive Summary
Neumora Therapeutics reported Q2 2026 EPS of -$0.23, exactly in line with consensus, with no revenue. Cash and equivalents of $116.8M are expected to fund operations into Q3 2027. Pipeline milestones remain on track for H2 2026, including data readouts for NMRA-511 and NMRA-898, and an IND submission for NMRA-215. Leadership changes include a new CEO and CMO.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.23 in line with consensus of -$0.23
- Cash and cash equivalents of $116.8M as of June 30, 2026; cash runway into Q3 2027
- Net loss improved to $43.1M from $52.7M in Q2 2025
- R&D expense decreased to $29.3M from $38.7M YoY
- NMRA-215 IND submission planned for Q4 2026 with Phase 1 start by end of 2026
- NMRA-511 MAD expansion cohort data in AD agitation expected Q4 2026
- NMRA-898 Phase 1 data in schizophrenia expected H2 2026
- Joshua Pinto, Ph.D., appointed CEO; Doron Sagman, M.D., appointed CMO
Financial Impact
No material financial impact; net loss improved 18% YoY but remains significant relative to cash position.
Risk Factors
- Clinical trial failures or delays for pipeline candidates
- Dilution risk if additional capital is needed beyond current cash runway
- Leadership transition execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345232 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | 144 | $1.63 $0.6918 | ▲ +57.56% | ▲ +57.03% | $0.4999 (+69.33%) |
Aug 17, 2026 6w ago | 144 | $1.64 $0.7732 | ▲ +52.85% | ▲ +51.54% | $0.4999 (+69.52%) |
Aug 14, 2026 7w ago | 8-K | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Aug 14, 2026 7w ago | Press Release | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Jul 27, 2026 9w ago | 8-K | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jul 27, 2026 9w ago | Press Release | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jun 15, 2026 15w ago | 8-K | $0.9145 $1.60 | ▼ −74.96% | ▼ −75.71% | $0.4999 (+45.34%) |
Apr 17, 2026 24w ago | DEFA14A | $2.19 $1.77 | ▼ −19.18% | ▼ −23.38% | $0.4999 (−77.17%) |
Mar 30, 2026 26w ago | Press Release | $1.93 $2.25 | ▲ +16.58% | ▲ +3.98% | $0.4999 (−74.10%) |
Mar 16, 2026 28w ago | Press Release | $2.87 $2.03 | ▼ −29.27% | ▼ −33.05% | $0.4999 (−82.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access